JP6371526B2 - タウを認識するリン酸化部位特異的抗体 - Google Patents

タウを認識するリン酸化部位特異的抗体 Download PDF

Info

Publication number
JP6371526B2
JP6371526B2 JP2013532226A JP2013532226A JP6371526B2 JP 6371526 B2 JP6371526 B2 JP 6371526B2 JP 2013532226 A JP2013532226 A JP 2013532226A JP 2013532226 A JP2013532226 A JP 2013532226A JP 6371526 B2 JP6371526 B2 JP 6371526B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
antibody
acid sequence
tau
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013532226A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014502141A (ja
JP2014502141A5 (cg-RX-API-DMAC7.html
Inventor
アンドレア ファイファー，
アンドレア ファイファー，
アンドレアス ムース，
アンドレアス ムース，
ルーヴェン， フレッド ヴァン
ルーヴェン， フレッド ヴァン
マリア ピルグレン，
マリア ピルグレン，
オスカル アドルフソン，
オスカル アドルフソン，
Original Assignee
エーシー イミューン エス．エー．
エーシー イミューン エス．エー．
カトリーケ ユニヴェルシテート ルーヴェン
カトリーケ ユニヴェルシテート ルーヴェン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44947048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6371526(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by エーシー イミューン エス．エー．, エーシー イミューン エス．エー．, カトリーケ ユニヴェルシテート ルーヴェン, カトリーケ ユニヴェルシテート ルーヴェン filed Critical エーシー イミューン エス．エー．
Publication of JP2014502141A publication Critical patent/JP2014502141A/ja
Publication of JP2014502141A5 publication Critical patent/JP2014502141A5/ja
Application granted granted Critical
Publication of JP6371526B2 publication Critical patent/JP6371526B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
JP2013532226A 2010-10-07 2011-10-07 タウを認識するリン酸化部位特異的抗体 Active JP6371526B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10186810 2010-10-07
EP10186810.7 2010-10-07
EP11174248 2011-07-15
EP11174248.2 2011-07-15
PCT/EP2011/067604 WO2012045882A2 (en) 2010-10-07 2011-10-07 Pharmaceutical composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017008740A Division JP2017113004A (ja) 2010-10-07 2017-01-20 薬学的組成物

Publications (3)

Publication Number Publication Date
JP2014502141A JP2014502141A (ja) 2014-01-30
JP2014502141A5 JP2014502141A5 (cg-RX-API-DMAC7.html) 2016-06-23
JP6371526B2 true JP6371526B2 (ja) 2018-08-08

Family

ID=44947048

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013532226A Active JP6371526B2 (ja) 2010-10-07 2011-10-07 タウを認識するリン酸化部位特異的抗体
JP2017008740A Pending JP2017113004A (ja) 2010-10-07 2017-01-20 薬学的組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017008740A Pending JP2017113004A (ja) 2010-10-07 2017-01-20 薬学的組成物

Country Status (29)

Country Link
US (2) US9304138B2 (cg-RX-API-DMAC7.html)
EP (2) EP2625198B1 (cg-RX-API-DMAC7.html)
JP (2) JP6371526B2 (cg-RX-API-DMAC7.html)
KR (1) KR101988672B1 (cg-RX-API-DMAC7.html)
CN (1) CN103502272B (cg-RX-API-DMAC7.html)
AR (1) AR085198A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011311516B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013008333B1 (cg-RX-API-DMAC7.html)
CA (1) CA2812865C (cg-RX-API-DMAC7.html)
CL (1) CL2013000951A1 (cg-RX-API-DMAC7.html)
CO (1) CO6710903A2 (cg-RX-API-DMAC7.html)
CR (1) CR20130160A (cg-RX-API-DMAC7.html)
DK (1) DK2625198T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP13012609A (cg-RX-API-DMAC7.html)
ES (1) ES2548686T3 (cg-RX-API-DMAC7.html)
HK (1) HK1216897A1 (cg-RX-API-DMAC7.html)
HU (1) HUE027649T2 (cg-RX-API-DMAC7.html)
IL (1) IL225568A (cg-RX-API-DMAC7.html)
MX (1) MX338421B (cg-RX-API-DMAC7.html)
MY (1) MY164376A (cg-RX-API-DMAC7.html)
PE (1) PE20140218A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013500615A1 (cg-RX-API-DMAC7.html)
PL (1) PL2625198T3 (cg-RX-API-DMAC7.html)
RU (1) RU2603078C2 (cg-RX-API-DMAC7.html)
SG (1) SG189136A1 (cg-RX-API-DMAC7.html)
SI (1) SI2625198T1 (cg-RX-API-DMAC7.html)
TW (1) TW201216985A (cg-RX-API-DMAC7.html)
WO (1) WO2012045882A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201302432B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017113004A (ja) * 2010-10-07 2017-06-29 エーシー イミューン エス．エー． 薬学的組成物

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10266585B2 (en) * 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
US8940272B2 (en) 2010-10-11 2015-01-27 University Of Zurich Human anti-tau antibodies
CA2826286C (en) * 2011-01-31 2021-09-21 Intellect Neurosciences Inc. Treatment of tauopathies
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
EP2747778B1 (en) 2011-08-26 2017-12-06 Wisconsin Alumni Research Foundation Influenza viruses with mutant pb2 gene segment as live attenuated vaccines
CN108034005B (zh) * 2011-10-07 2021-06-25 Ac免疫有限公司 识别Tau的磷酸化特异抗体
AU2012359039B2 (en) 2011-12-20 2017-08-24 Janssen Biotech, Inc. Anti-PHF-tau antibodies and their uses
WO2013151762A1 (en) 2012-04-05 2013-10-10 Ac Immune S.A. Humanized tau antibody
MX359555B (es) * 2012-07-03 2018-10-02 Univ Washington Anticuerpos para tau.
WO2014016737A1 (en) * 2012-07-24 2014-01-30 Pfizer Inc. Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof
EP3685854A1 (en) 2012-08-16 2020-07-29 Ipierian, Inc. Methods of treating a tauopathy
US12024568B2 (en) 2012-09-13 2024-07-02 Cornell University Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
SG11201504822VA (en) * 2012-12-21 2015-07-30 Biogen Idec Internat Neuroscience Gmbh Human anti-tau antibodies
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CN105143258B (zh) * 2013-03-15 2020-06-23 Ac免疫有限公司 抗Tau抗体和使用方法
CA2914369C (en) 2013-06-06 2023-02-14 Igenica Biotherapeutics, Inc. Anti-c10orf54 antibodies and uses thereof
GB201312226D0 (en) * 2013-07-08 2013-08-21 Adx Neurosciences Improved antibodies
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
BR112016010454A2 (pt) * 2013-11-27 2017-12-05 Ipierian Inc métodos para tratar uma taupatia
RS60031B1 (sr) 2013-12-20 2020-04-30 Hoffmann La Roche Humanizovana anti-tau(ps422) antitela i načini upotrebe
WO2015122922A1 (en) 2014-02-14 2015-08-20 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
JP6679582B2 (ja) 2014-09-30 2020-04-15 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ タウの動態測定
CN107428820B (zh) * 2014-11-19 2022-03-22 阿克松神经系统科学公司 在阿尔茨海默氏病中的人源化tau抗体
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
TWI669314B (zh) 2015-02-26 2019-08-21 美國禮來大藥廠 針對ｔａｕ之抗體及其用途
JP6793134B2 (ja) 2015-06-05 2020-12-02 ジェネンテック， インコーポレイテッド 抗ｔａｕ抗体及び使用方法
PL3313877T3 (pl) 2015-06-24 2020-11-02 F. Hoffmann-La Roche Ag Humanizowane przeciwciała przeciwko białku tau(pS422) i sposoby stosowania
EA037092B1 (ru) 2015-07-06 2021-02-04 Юсб Биофарма Срл Тау-связывающие антитела
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
WO2017027691A1 (en) 2015-08-13 2017-02-16 New York University Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy
US11197925B2 (en) 2016-02-19 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Influenza B virus replication for vaccine development
HUE053679T2 (hu) * 2016-07-12 2021-07-28 H Lundbeck As Hiperfoszforilezett TAU-ra specifikus antitestek és eljárások ezek alkalmazására
JP6949102B2 (ja) 2016-08-09 2021-10-13 イーライ リリー アンド カンパニー 併用療法
MY198942A (en) 2016-12-07 2023-10-03 Genentech Inc Anti-tau antibodies and methods of use
WO2018106776A2 (en) 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
US10995137B2 (en) 2017-01-04 2021-05-04 H. Lundbeck A/S Antibodies specific for hyperphosphorlated tau for the treatment of ocular diseases
WO2018152359A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
JOP20180014A1 (ar) * 2017-02-27 2019-01-30 Teijin Pharma Ltd جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه
EA039569B1 (ru) * 2017-03-14 2022-02-11 Х. Лундбекк А/С Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
WO2018217630A1 (en) * 2017-05-21 2018-11-29 University Of Tennessee Research Foundation Methods and compositions for targeting tissue lesions
TWI853617B (zh) 2017-10-16 2024-08-21 日商衛材R&D企管股份有限公司 抗tau抗體及其用途
US11197926B2 (en) 2017-10-25 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
CN111698937A (zh) * 2017-11-28 2020-09-22 国立大学法人三重大学 检测方法
KR20200130350A (ko) 2018-03-05 2020-11-18 얀센 파마슈티카 엔.브이. 항-phf-타우 항체 및 이의 용도
JP2021530552A (ja) 2018-07-31 2021-11-11 イーライ リリー アンド カンパニー 併用療法
WO2020033527A2 (en) 2018-08-07 2020-02-13 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
WO2020041311A1 (en) 2018-08-20 2020-02-27 Wisconsin Alumni Research Foundation Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (ha) protein
WO2020073917A1 (en) * 2018-10-09 2020-04-16 Single Cell Technology, Inc. Anti-bcma antibodies
WO2020077380A1 (en) * 2018-10-17 2020-04-23 The University Of Queensland Methods and compositions for treating tauopathies
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
WO2020142659A2 (en) * 2019-01-04 2020-07-09 Trio Pharmaceuticals, Inc. Multi-specific protein molecules and uses thereof
EP3921413A1 (en) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
WO2020201828A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
WO2020210247A1 (en) * 2019-04-12 2020-10-15 Phanes Therapeutics, Inc. Humanized anti-folate receptor 1 chimeric antigen receptors and uses thereof
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
CN110028583B (zh) * 2019-05-07 2020-09-11 温州医科大学 抗Tau抗体及其在治疗阿尔茨海默病、创伤性脑损伤中的应用
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
CN112752251B (zh) * 2019-10-29 2022-05-06 中国移动通信有限公司研究院 一种ue标识符的分配方法、装置和计算机可读存储介质
WO2021150874A1 (en) 2020-01-24 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized na
US20230349924A1 (en) * 2020-02-05 2023-11-02 Sumitomo Pharma Co., Ltd. Determination agent and determination method for tauopathy and dementia-related diseases
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
US11702467B2 (en) 2020-06-25 2023-07-18 Merck Sharp & Dohme Llc High affinity antibodies targeting tau phosphorylated at serine 413
CA3205586A1 (en) * 2020-12-16 2022-06-23 Voyager Therapeutics, Inc. Tau binding compounds
EP4014997A1 (en) 2020-12-16 2022-06-22 Consejo Superior de Investigaciones Científicas (CSIC) Stard1 inhibitors for the treatment of lysosomal disorders
CA3208580A1 (en) * 2021-03-18 2022-09-22 Hector De Jesus RINCON ARANO Anti-alpp/alppl2 antibodies and antibody-drug conjugates
CL2021001380A1 (es) 2021-05-26 2022-01-14 Corporacion Centro Int De Biomedicina Icc Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias.
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
JP2025535203A (ja) 2022-09-15 2025-10-23 ボイジャー セラピューティクス インコーポレイテッド タウ結合化合物
WO2024163923A2 (en) * 2023-02-02 2024-08-08 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Phosphomimetic mutants, phosphospecific antibodies, and uses thereof
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025128975A1 (en) * 2023-12-14 2025-06-19 Immunitas Therapeutics, Inc. Cd161 binding proteins and related methods
WO2025134068A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Antibody drug conjugates targeting proteinopathies, and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
DE69233723T2 (de) 1991-12-06 2009-02-05 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Verwendung von Proteinkinasen zur Diagnose und Behandlung der Alzheimer Krankheit
DE69328430T2 (de) 1992-07-27 2001-01-25 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Zielgerichte liposome zur blut-hirne schranke
BR9509421A (pt) 1994-10-21 1997-09-30 Innogenetics Nv Novas sequências de genotipos de vírus de hepatite C e uso como agentes profiláticos terapêuticos e diagnósticos
US5756662A (en) 1995-03-14 1998-05-26 Corixa Corporation Compounds and methods for the detection of T. cruzi infection
WO1997034145A1 (fr) * 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
AU5508798A (en) * 1996-11-19 1998-06-10 Trustees Of The University Of Pennsylvania, The Diagnostic and therapeutic reagents for alzheimer's disease
US20050221391A1 (en) 2000-07-11 2005-10-06 Peter Davies Reagents and methods for identification of binding agents
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
AU2001286930A1 (en) 2000-08-30 2002-03-13 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
EP1554572B1 (en) 2001-07-25 2009-10-14 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
KR101111477B1 (ko) 2002-12-03 2012-02-23 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 치료제와 연결된 콜레스테롤을 포함하는 접합체
CA2511599A1 (en) 2002-12-24 2004-07-15 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
US20050089473A1 (en) 2003-09-10 2005-04-28 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
US7238788B2 (en) * 2004-02-18 2007-07-03 University Of Iowa Foundation Antibodies to phosphorylated tau, methods of making and methods of use
EP1812062B1 (en) * 2004-10-25 2022-03-09 Merck Sharp & Dohme Corp. Anti-addl antibodies and uses thereof
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20080220449A1 (en) * 2007-02-08 2008-09-11 Oligomerix, Inc. Biomarkers and assays for Alzheimer's disease
CA2692039C (en) 2007-06-13 2019-07-02 Research Development Foundation Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling
KR20100115340A (ko) 2007-10-19 2010-10-27 이무나스 파마 가부시키가이샤 Ａβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용
HUE055739T2 (hu) * 2009-03-18 2021-12-28 Ac Immune Sa Eljárás terápiás alkalmazásra
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
CA2765099A1 (en) * 2009-06-10 2010-12-16 New York University Phosphorylated tau peptide for use in the treatment of tauopathy
MX2012001194A (es) * 2009-07-30 2012-03-07 Pfizer Vaccines Llc Peptidos tau antigenicos y usos de los mismos.
EP2625198B1 (en) * 2010-10-07 2015-07-22 AC Immune S.A. Antibodies recognising phospho-tau

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017113004A (ja) * 2010-10-07 2017-06-29 エーシー イミューン エス．エー． 薬学的組成物

Also Published As

Publication number Publication date
ECSP13012609A (es) 2013-07-31
CO6710903A2 (es) 2013-07-15
EP2987807A2 (en) 2016-02-24
CA2812865C (en) 2021-01-26
SI2625198T1 (sl) 2015-11-30
KR20130115279A (ko) 2013-10-21
IL225568A0 (en) 2013-06-27
ES2548686T3 (es) 2015-10-20
HUE027649T2 (en) 2016-10-28
PL2625198T3 (pl) 2015-12-31
JP2014502141A (ja) 2014-01-30
US20120276009A1 (en) 2012-11-01
HK1216897A1 (en) 2016-12-09
CA2812865A1 (en) 2012-04-12
AU2011311516A1 (en) 2013-04-18
IL225568A (en) 2017-06-29
BR112013008333A2 (pt) 2021-09-21
HK1187928A1 (zh) 2014-04-17
WO2012045882A3 (en) 2012-05-31
TW201216985A (en) 2012-05-01
CL2013000951A1 (es) 2014-01-03
RU2013120544A (ru) 2014-11-20
PE20140218A1 (es) 2014-03-01
US20160304590A1 (en) 2016-10-20
BR112013008333B1 (pt) 2022-10-11
CR20130160A (es) 2013-09-03
US9304138B2 (en) 2016-04-05
DK2625198T3 (en) 2015-09-28
MX338421B (es) 2016-04-15
AU2011311516B2 (en) 2015-06-11
US10100104B2 (en) 2018-10-16
RU2603078C2 (ru) 2016-11-20
WO2012045882A2 (en) 2012-04-12
EP2625198A2 (en) 2013-08-14
AR085198A1 (es) 2013-09-18
CN103502272B (zh) 2016-06-15
SG189136A1 (en) 2013-05-31
MX2013003800A (es) 2013-06-28
EP2987807A3 (en) 2016-06-01
EP2625198B1 (en) 2015-07-22
KR101988672B1 (ko) 2019-06-12
ZA201302432B (en) 2016-07-27
MY164376A (en) 2017-12-15
JP2017113004A (ja) 2017-06-29
PH12013500615A1 (en) 2013-06-03
CN103502272A (zh) 2014-01-08

Similar Documents

Publication Publication Date Title
JP6371526B2 (ja) タウを認識するリン酸化部位特異的抗体
CN104080806B (zh) 识别Tau的磷酸化特异抗体
JP6293731B2 (ja) ヒト化タウ抗体
AU2013205313B2 (en) Phosphospecific antibodies recognising tau
HK1187928B (en) Antibodies recognising phospho-tau
AU2016202289A1 (en) Phosphospecific antibodies recognising tau
HK1200469B (en) Phosphospecific antibodies recognising tau
TW201321409A (zh) 醫藥組合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160121

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20160427

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170120

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170310

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20170512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180713

R150 Certificate of patent or registration of utility model

Ref document number: 6371526

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250